2021 대한부정맥학회 심방세동 환자의 뇌졸중 예방 관리 지침

키워드

참고문헌 (133)

1. Pisters R, "Stroke and thromboembolism in atrial fibrillation", Circ J, 76, pp.2289~2304 (2012)
2. Szymanski FM, "Stroke risk factors beyond the CHA₂DS₂-VASc score : can we improve our identification of"high stroke risk"patients with atrial fibrillation?", Am J Cardiol, 116, pp.1781~1788 (2015)
3. Ganesan AN, "The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding : a systematic review and meta-analysis", Eur Heart J, 37, pp.1591~1602 (2016)
4. Allan V, "Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants", Thromb Haemost, 117, pp.837~850 (2017)
5. Banerjee A, "Ejection fraction and outcomes in patients with atrial fibrillation and heart failure : the Loire Valley Atrial Fibrillation Project", Eur J Heart Fail, 14, pp.295~301 (2012)
6. Lee SE, "Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy", Heart, 10, pp.1496~1501 (2017)
7. Shin SY, "Identification of markers associated with development of stroke in "clinically low-risk" atrial fibrillation patients", J Am Heart Assoc., 8, pp.e012697~ (2019)
8. Kang SH, "Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants-Korean nationwide population-based study", Circ J, 81, pp.1158~1164 (2017)
9. Jung H, "Stroke risk stratification for atrial fibrillation patients with hypertrophic cardiomyopathy", J Am Coll Cardiol, 72, pp.2409~2411 (2018)
10. Wu VC, "Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation", Heart, 106, pp.534~540 (2020)
11. Tomasdottir M, "Risk of ischemic stroke and utility of CHA2 DS2-VASc score in women and men with atrial fibrillation", Clin Cardiol, 42, pp.1003~1009 (2019)
12. Friberg L, "Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study", BMJ, 344, pp.e3522~ (2012)
13. Overvad TF, "Stroke risk stratification:CHA2DS2-VA or CHA2DS2-VASc?", Heart Lung Circ, 28, pp.e14~e15 (2019)
14. Nielsen PB, "Female sex as a risk modifier for stroke risk in atrial fibrillation : using CHA2DS2-VASc versus CHA2DS2-VA for stroke risk stratification in atrial fibrillation : a note of caution", Thromb Haemost, 120, pp.894~898 (2020)
15. Nielsen PB, "Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation : should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?", Circulation, 137, pp.832~840 (2018)
16. Marzona I, "Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation : a systematic review and meta-analysis of 993, 600 patients", Int J Cardiol, 269, pp.182~191 (2018)
17. , vascular disease, age 65-74, female)for stroke in Asian patients with atrial fibrillation : a Korean nationwide sample cohort study, "Stroke", 2017, 1524~1530
18. Kim TH, "CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke : a Korean nationwide cohort study", Stroke, 48, pp.2984~2990 (2017)
19. Vinereanu D, "Echocardiographic risk factors for stroke and outcomes in patients with atrial fibrillation anticoagulated with apixaban or warfarin", Stroke, 48, pp.3266~3273 (2017)
20. "Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3clinical trials", Arch Intern Med., 158, pp.1316~1320 (1998)
21. Friberg L, "Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure : the Swedish atrial fibrillation cohort study", Eur Heart J, 36, pp.297~306 (2015)
22. Poli M, "Atrial fibrillation is a major cause of stroke in apneic patients : a prospective study", Sleep Med, 30, pp.251~254 (2017)
23. Bassand JP, "Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation", PLoS One, 13, pp.e0191592~ (2018)
24. Overvad TF, "Body mass index and adverse events in patients with incident atrial fibrillation", Am J Med, 126, pp.640~ (2013)
25. Lee JM, "Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low CHA2DS2-VASc scores", Heart Rhythm, 14, pp.1297~1301 (2017)
26. Baek YS, "Associations of abdominal obesity and new-onset atrial fibrillation in the general population", J Am Heart Assoc., 6, pp.e004705~ (2017)
27. Kim TH, "Left ventricular diastolic dysfunction is associated with atrial remodeling and risk or presence of stroke in patients with paroxysmal atrial fibrillation", J Cardiol, 68, pp.104~109 (2016)
28. Hijazi Z, "Application of biomarkers for risk stratification in patients with atrial fibrillation", Clin Chem, 63, pp.152~164 (2017)
29. 이기홍, "Association between Serum Parathyroid Hormone Levels and the Prevalence of Atrial Fibrillation: the Dong-gu Study", Korean Circulation Journal, 48(2), pp.159~167 (2018), 대한심장학회[DOI]
30. Lip GY, "Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation", Stroke, 37, pp.2294~2300 (2006)
31. Chao TF, "Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants : a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors", Thromb Haemost, 118, pp.768~777 (2018)
32. Man-Son-Hing M, "Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls", Arch Intern Med, 159, pp.677~685 (1999)
33. Esteve-Pastor MA, "Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores. The murcia atrial fibrillation project", Thromb Haemost, 117, pp.1848~1858 (2017)
34. Borre ED, "Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation : a systematic review", Thromb Haemost, 118, pp.2171~2187 (2018)
35. Caldeira D, "Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation : a systematic review and meta-analysis", J Interv Card Electrophysiol, 40, pp.277~284 (2014)
36. Chang G, "Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation : a network meta-analysis", J Thromb Haemost, 18, pp.791~801 (2020)
37. Zhu W, "The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation : a systematic review and meta-analysis", Clin Cardiol, 38, pp.555~561 (2015)
38. Berg DD, "Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48", Circulation, 139, pp.760~771 (2019)
39. Hijazi Z, "The novel biomarker-based ABC(age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation : a derivation and validation study", Lancet, 387, pp.2302~2311 (2016)
40. Lip GY, "Bleeding risk assessment in atrial fibrillation : observations on the use and misuse of bleeding risk scores", J Thromb Haemost, 14, pp.1711~1714 (2016)
41. Hart RG, "Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
42. De Caterina R, "Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease", Thromb Haemost, 110, pp.1087~1107 (2013)
43. Choi WS, "Optimal international normalized ratio for warfarin therapy in elderly Korean patients with non-valvular atrial fibrillation", Int J Arrhythm, 17, pp.167~173 (2016)
44. Lee IH, "Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea", J Cardiol, 66, pp.475~481 (2015)
45. Wan Y, "Anticoagulation control and prediction of adverse events in patients with atrial fibrillation : a systematic review", Circ Cardiovasc Qual Outcomes, 1, pp.84~91 (2008)
46. Ki Hong Lee, "Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?", Korean Circulation Journal, 50(2), pp.163~175 (2020), 대한심장학회[DOI]
47. Amin A, "Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials", J Thromb Thrombolysis, 38, pp.150~159 (2014)
48. Själander S, "Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation", Thromb Res, 167, pp.113~118 (2018)
49. Proietti M, "Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant : using the SAMe-TT2R2 score", Eur Heart J Cardiovasc Pharmacother, 1, pp.150~152 (2015)
50. Apostolakis S, "Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin : the SAMe-TT₂R₂ score", Chest, 144, pp.1555~1563 (2013)
51. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
52. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
53. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
54. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
55. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
56. Wang KL, "Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation : meta-analysis", Stroke, 46, pp.2555~2561 (2015)
57. Cha MJ, "Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation", Stroke, 48, pp.3040~3048 (2017)
58. Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
59. Camm AJ, "XANTUS : a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation", Eur Heart J, 37, pp.1145~1153 (2016)
60. Carmo J, "Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists", Thromb Haemost, 116, pp.754~763 (2016)
61. Huisman MV, "Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation : global registry on long-term antithrombotic treatment in patients with atrial fibrillation(GLORIA-AF)registry", Am Heart J, 198, pp.55~63 (2018)
62. Lee SR, "Edoxaban in Asian patients with atrial fibrillation : effectiveness and safety", J Am Coll Cardiol, 72, pp.838~853 (2018)
63. Li XS, "Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients", Thromb Haemost, 117, pp.1072~1082 (2017)
64. Martínez CAA, "XANTUS-EL : a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America", Egypt Heart J, 70, pp.307~313 (2018)
65. Lee KH, "Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation", Europace, 19(Suppl 4), pp.iv1~iv9 (2017)
66. Ingrasciotta Y, "Pharmacokinetics of new oral anticoagulants : implications for use in routine care", Expert Opin Drug Metab Toxicol, 14, pp.1057~1069 (2018)
67. Lee KH, "Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction", Europace, 17(Suppl 2), pp.ii69~ii75 (2015)
68. Lee SR, "Optimal rivaroxaban dose in Asian patients with atrial fibrillation and normal or mildly impaired renal function", Stroke, 50, pp.1140~1148 (2019)
69. Siontis KC, "Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States", Circulation, 138, pp.1519~1529 (2018)
70. Stanton BE, "Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment", Pharmacotherapy, 37, pp.412~419 (2017)
71. Steinberg BA, "Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes : the ORBIT-AF II Registry", J Am Coll Cardiol, 68, pp.2597~2604 (2016)
72. Yao X, "Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction", J Am Coll Cardiol, 69, pp.2779~2790 (2017)
73. 이소령, "Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation", Yonsei Medical Journal, 60(3), pp.277~284 (2019), 연세대학교의과대학[DOI]
74. Lee KN, "Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients", Sci Rep, 10, pp.1801~ (2020)
75. Cho MS, "Outcomes after use of standardand low-dose non-vitamin K oral anticoagulants in Asian patients with atrial fibrillation", Stroke, 50, pp.110~118 (2018)
76. 정보영, "Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients", Korean Circulation Journal, 47(6), pp.833~841 (2017), 대한심장학회[DOI]
77. ACTIVE Writing Group of the ACTIVE Investigators, "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events(ACTIVE W) : a randomised controlled trial", Lancet, 367, pp.1903~1912 (2006)
78. ACTIVE Investigators, "Effect of clopidogrel added to aspirin in patients with atrial fibrillation", N Engl J Med, 360, pp.2066~2078 (2009)
79. Själander S, "Atrial fibrillation patients do not benefit from acetylsalicylic acid", Europace, 16, pp.631~638 (2014)
80. Lip GY, "The role of aspirin for stroke prevention in atrial fibrillation", Nat Rev Cardiol, 8, pp.602~606 (2011)
81. Mant J, "Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the birmingham atrial fibrillation treatment of the aged study, BAFTA) : a randomised controlled trial", Lancet, 370, pp.493~503 (2007)
82. Holmes DR, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation : a randomised non-inferiority trial", Lancet, 374, pp.534~542 (2009)
83. Reddy VY, "Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation : the ASAP study(ASA plavix feasibility study with watchman left atrial appendage closure technology)", J Am Coll Cardiol, 61, pp.2551~2556 (2013)
84. Reddy VY, "Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial", Circulation, 127, pp.720~729 (2013)
85. Holmes DR Jr, "Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy : the PREVAIL trial", J Am Coll Cardiol, 64, pp.1~12 (2014)
86. Boersma LV, "Implant success and safety of left atrial appendage closure with the WATCHMAN device : peri-procedural outcomes from the EWOLUTION registry", Eur Heart J, 37, pp.2465~2474 (2016)
87. Boersma LV, "Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation : 1-year follow-up outcome data of the EWOLUTION trial", Heart Rhythm, 14, pp.1302~1308 (2017)
88. Badheka AO, "Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States : influence of hospital volume", Circ Arrhythm Electrophysiol, 8, pp.42~48 (2015)
89. Pison L, "Left atrial appendage closure-indications, techniques, and outcomes : results of the European Heart Rhythm Association Survey", Europace, 17, pp.642~646 (2015)
90. Price MJ, "Early safety and efficacy of percutaneous left atrial appendage suture ligation:results from the U.S. transcatheter LAA ligation consortium", J Am Coll Cardiol, 64, pp.565~572 (2014)
91. Fauchier L, "Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation", J Am Coll Cardiol, 71, pp.1528~1536 (2018)
92. Lakkireddy D, "Short and long-term outcomes of percutaneous left atrial appendage suture ligation : results from a US multicenter evaluation", Heart Rhythm, 13, pp.1030~1036 (2016)
93. van Laar C, "Thoracoscopic left atrial appendage clipping : a multicenter cohort analysis", JACC Clin Electrophysiol, 4, pp.893~901 (2018)
94. Healey JS, "Left atrial appendage occlusion study(LAAOS) : results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke", Am Heart J, 150, pp.288~293 (2005)
95. Whitlock RP, "Left atrial appendage occlusion study II(LAAOS II)", Can J Cardiol, 29, pp.1443~1447 (2013)
96. Tsai YC, "Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation : a meta-analysis", Eur J Cardiothorac Surg, 47, pp.847~854 (2015)
97. Aryana A, "Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization", Heart Rhythm, 12, pp.1431~1437 (2015)
98. Gillinov AM, "Surgical ablation of atrial fibrillation during mitral-valve surgery", N Engl J Med, 372, pp.1399~1409 (2015)
99. Whitlock R, "Rationale and design of the left atrial appendage occlusion study(LAAOS)III", Ann Cardiothorac Surg, 3, pp.45~54 (2014)
100. Chao TF, "Oral anticoagulation in very elderly patients with atrial fibrillation : a nationwide cohort study", Circulation, 138, pp.37~47 (2018)
101. Nielsen PB, "Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study", BMJ, 356, pp.j510~ (2017)
102. Larsen TB, "Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study", BMJ, 353, pp.i3189~ (2016)
103. Tilz RR, "Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey", Europace, 19, pp.1737~1742 (2017)
104. Ogawa H, "Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events", Stroke, 49, pp.2301~2308 (2018)
105. Potpara TS, "A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation : implications of arrhythmia progression on prognosis : the Belgrade atrial fibrillation study", Chest, 141, pp.339~347 (2012)
106. Mahajan R, "Subclinical device-detected atrial fibrillation and stroke risk : a systematic review and meta-analysis", Eur Heart J, 39, pp.1407~1415 (2018)
107. Brambatti M, "Temporal relationship between subclinical atrial fibrillation and embolic events", Circulation, 129, pp.2094~2099 (2014)
108. Boriani G, "Device-detected atrial fibrillation and risk for stroke : an analysis of >10, 000patients from the SOS AF project(stroke prevention strategies based on atrial fibrillation information from implanted devices)", Eur Heart J, 35, pp.508~516 (2014)
109. Freedman B, "Screening for atrial fibrillation : a report of the AF-SCREEN international collaboration", Circulation, 135, pp.1851~1867 (2017)
110. Freedman B, "Management of atrial high-rate episodes detected by cardiac implanted electronic devices", Nat Rev Cardiol, 14, pp.701~714 (2017)
111. Camm AJ, "Atrial high-rate episodes and stroke prevention", Europace, 19, pp.169~179 (2017)
112. Boriani G, "Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden", Heart Rhythm, 15, pp.376~383 (2018)
113. Pastori D, "Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants", Int J Cardiol, 264, pp.58~63 (2018)
114. Kuo L, "Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?", J Am Heart Assoc., 6, pp.e005307~ (2017)
115. Lee SR, "Direct oral anticoagulants in patients with atrial fibrillation and liver disease", J Am Coll Cardiol, 73, pp.3295~3308 (2019)
116. Staerk L, "Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation:nationwide cohort study", BMJ, 351, pp.h5876~ (2015)
117. Eckman MH, "Moving the tipping point : the decision to anticoagulate patients with atrial fibrillation", Circ Cardiovasc Qual Outcomes, 4, pp.14~21 (2011)
118. Proietti M, "Major S outcomes in atrial fibrillation patients with one risk factor : impact of time in therapeutic range observations from the PORTIF trials", Am J Med, 129, pp.1110~1116 (2016)
119. Lip GY, "Should Patients with atrial fibrillation and 1 stroke risk factor(CHA2DS2-VASc score 1 in men, 2 in women)be anticoagulated? Yes : even 1 stroke risk factor confers a real risk of stroke", Circulation, 133, pp.1498~1503 (2016)
120. Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the Euro Heart Survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
121. Kim D, "Ideal blood pressure in patients with atrial fibrillation", J Am Coll Cardiol, 72, pp.1233~1245 (2018)
122. Nielsen PB, "Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds : a nationwide cohort study", Sci Rep, 6, pp.27410~ (2016)
123. Pisters R, "A novel user-friendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)
124. Böhm M, "Changes in renal function in patients with atrial fibrillation : an analysis from the RE-LY trial", J Am Coll Cardiol, 65, pp.2481~2493 (2015)
125. Hijazi Z, "Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time : insights from the ARISTOTLE randomized clinical trial", JAMA Cardiol, 1, pp.451~460 (2016)
126. Potpara TS, "Reliable identification of"truly low"thromboembolic risk in patients initially diagnosed with"lone"atrial fibrillation : the Belgrade atrial fibrillation study", Circ Arrhythm Electrophysiol, 5, pp.319~326 (2012)
127. Weijs B, "Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk : a 10-year follow-up study", Neth Heart J, 27, pp.487~497 (2019)
128. Chao TF, "Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0(males)or 1(females) : implications for reassessment of stroke risk in initially 'low-risk' patients", Thromb Haemost, 119, pp.1162~1170 (2019)
129. Clarkesmith DE, "Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial", PLoS One, 8, pp.e74037~ (2013)
130. Teiger E, "Percutaneous left atrial appendage closure is a reasonable option for patients with atrial fibrillation at high risk for cerebrovascular events", Circ Cardiovasc Interv., 11, pp.e005841~ (2018)
131. Hart RG, "Stroke with intermittent atrial fibrillation:incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators", J Am Coll Cardiol, 35, pp.183~187 (2000)
132. Saw J, "Early Canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure", J Cardiovasc Electrophysiol, 28, pp.396~401 (2017)
133. Martin Gutierrez E, "Beneficial effect of left atrial appendage closure during cardiac surgery : a meta-analysis of 280 585 patients", Eur J Cardiothorac Surg, 57, pp.252~262 (2020)

관련 논문AI추천